Teclistamab in relapsed or refractory multiple myeloma
P Moreau, AL Garfall, NWCJ van de Donk… - … England Journal of …, 2022 - Mass Medical Soc
Background Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
[引用][C] Teclistamab in Relapsed or Refractory Multiple Myeloma
P Moreau, AL Garfall… - New England …, 2022 - produccioncientifica.usal.es
BACKGROUND Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
Teclistamab in Relapsed or Refractory Multiple Myeloma
P Moreau, AL Garfall, NWCJ van de Donk… - New England Journal …, 2022 - cir.nii.ac.jp
Teclistamab in Relapsed or Refractory Multiple Myeloma | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
[HTML][HTML] Teclistamab in Relapsed or Refractory Multiple Myeloma
P Moreau, AL Garfall, N van de Donk… - The New England …, 2022 - ncbi.nlm.nih.gov
BACKGROUND Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
Teclistamab in Relapsed or Refractory Multiple Myeloma.
L Karlin, L Benboubker, MV Mateos… - The New England …, 2022 - escholarship.org
BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
Teclistamab in Relapsed or Refractory Multiple Myeloma
P Moreau, AL Garfall… - New England …, 2022 - researchinformation.amsterdamumc …
BACKGROUND Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
[引用][C] Teclistamab in Relapsed or Refractory Multiple Myeloma
P Moreau, AL Garfall… - New England …, 2022 - produccioncientifica.ucm.es
Teclistamab in Relapsed or Refractory Multiple Myeloma.
P Moreau, AL Garfall, N van de Donk… - The New England …, 2022 - europepmc.org
Background Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
[PDF][PDF] Teclistamab in Relapsed or Refractory Multiple Myeloma
P Moreau, AL Garfall, N van de Donk, H Nahi… - N Engl J …, 2022 - legeforeningen.no
BACKGROUND Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
Teclistamab in Relapsed or Refractory Multiple Myeloma
P Moreau, AL Garfall… - The New England …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …